The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
Welcome back to another edition of Endpoints Weekly! It’s Super Bowl weekend with the Patriots and Seahawks fighting for the championship. While our many Boston-area readers are surely excited, most of us here in New …
STAT+: HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy
FDA will take “decisive steps” to thwart companies from mass marketing unapproved, compounded versions of GLP-1 drugs
US calls for DOJ investigation of Hims over GLP-1 drugs
The US government said it will refer telehealth and GLP-1 company Hims & Hers to the Department of Justice for investigation, following the company’s controversial launch of a compounded version of Novo …
Synergizing global clinical trials data: GLP-1 receptor agonist safety and novel clinical applications
A research team led by the Department of Medicine, under the School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has synergized the impacts of worldwide clinical trial data through a series of meta-analyses on GLP‑1 receptor agonists, an emerging cardiometabolic drug, offering in-depth insights into its safety profile and novel therapeutic potential in treating cardiovascular diseases.
Use of GLP-1 Drugs Under Scrutiny at Winter Olympics
(MedPage Today) — As the Winter Olympic Games get underway, the World Anti-Doping Agency (WADA) is monitoring an unexpected class of drugs: GLP-1 receptor agonists.
An advisory group that makes recommendations about WADA’s list of prohibited…
STAT+: Pharmalittle: We’re reading about TrumpRx, Hims & Hers selling compounded Wegovy, and more
President Trump on Thursday night launched TrumpRx, the website he and his aides have touted as a platform aimed at lowering drug prices
STAT+: IPOs, GLP-1s, and challenges with a gene therapy
And other biotech news brought to you by The Readout
Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill
Novo Nordisk has also spoken out strongly against Hims & Hers’ compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.
Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown
I’ve been waiting for the big showdown between drugmakers and compounders for months, and it’s finally here.
Today on Post-Hoc Live at 12 p.m. ET, we’ll be talking about telehealth company Hims & Hers’ plan …
Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026
Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.